India Biotech Briefing. Dr. Brian W Tempest www.briantempest.com IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
Dr. Brian W Tempest
IBIZ Conference, NHS Expo
Excel London UK 9 March 2011
Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade.
Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also been Regional Director, Far East for Glaxo where he was responsible for businesses in Japan, China, Korea, and Taiwan.
Brian has worked in the Pharmaceutical Industry for the last 39 years and led Healthcare businesses in North America, South America, Europe, Africa, Middle East, Asia and India. He has also led sessions at Investor Meetings across Asia, Europe and USA. He is now an International Advisor to MAPE – India, Religare -India and UNCTAD - Switzerland. In addition he is a member of the SCRIP Global awards panel. Brian speaks at global conferences on the Challenge from India and China and more information on these presentations can be found on his website www.briantempest.com.
Brian has a PhD in Polymer Chemistry from Lancaster University and is a member of the Royal Society of Medicine, the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman of Hale & Tempest Co Ltd.
Fortis Global Healthcare
Engineers/Science graduates pa– India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m
Pharma Exports by Country
India Pharma Market Projections Source IPA
USA DMFs ex China Source FDA
Early discovery leads from USA, Europe or Singapore
Molecular optimisation from India
Toxicology from China, Central Europe, Singapore
Electronic Data Capture India
API Manufacture India
Drug Formulation Manufacture India, USA
Phase 1 Clinical Trials Europe
Phase 2,3 heavy use of India
Corporate back office India
Biosimilar Distributors Source IMS
Dr. Brian W Tempest
UK India Business Council
Manchester 10 March 2011